Roche confirmed its full-year outlook on Thursday, but posted profit that missed expectations for the first half of the year following an impairment charge at its diagnostics business.
Net profit at the Swiss pharmaceuticals company came in at 5.64 billion Swiss francs ($6.25 billion) in the first half, below forecasts of 5.98 billion Swiss francs by analysts in a Reuters poll. It marked a 7 percent fall on the same period last year.
It came after an impairment charge of 414 million Swiss francs related to "intangible assets" at its tissue diagnostics business.
Despite this, CEO Severin Schwan told CNBC he was "very happy" with Roche's performance over the first six months of the year.
"Price pressure continues, governments are under enormous pressure in terms of their healthcare budgets, however we, as a company, are very well positioned due to the innovative nature of our portfolio, and as such we are less exposed to price pressure," he said.